Sanofi stock price

Sanofi latest news:


  • 01/22/2018 09:03:35

    WRAPUP 2-Biotech M&A takes off as Sanofi and Celgene spend $20 billion

    * Large drugmakers scour for products from smaller biotechs (Adds detail on gains in other biotech shares)

  • 01/22/2018 08:57:16

    Biotech M&A takes off as Sanofi and Celgene spend $20 billion

    LONDON, Jan 22 (Reuters) - Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products for hemophilia and cancer to their medicine cabinets.

  • 01/22/2018 08:25:29

    Sanofi Moves to Acquire Bioverativ


  • 01/22/2018 07:32:45

    U.S. stocks open slightly lower in first trading day of government shutdown

    U.S. stocks fell modestly at the open on Monday, as investors found few reasons to keep pushing shares higher following a push to repeated records, and as the government shutdown provided another element of uncertainty to markets. The Dow Jones Industrial Average fell 72 points, or 0.2%, to 26,011. The S&P 500 declined 1 point to 2,809, a drop of less than 0.1%. The Nasdaq Composite Index was unchanged at 7,336. Both the S&P and the Nasdaq are coming off closing records, while the Dow is close to its own peak. While government shutdowns have historically not been big selling catalysts, uncertainty over when the government would reopened appeared to dampen buying enthusiasm. The Senate was expected to hold a procedural vote at noon Eastern Time on a measure that would keep the government funded through Feb. 8, but it wasn't clear if it would have enough support to advance. In company news, Juno Therapeutics Inc. jumped 27% after Celgene Corp. agreed to buy the company for $9 billion. Bioverativ Inc. soared 63% after Sanofi SA said it would buy it for $12 billion.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/22/2018 00:48:18

    Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion

    PARIS (Reuters) - French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, in a deal which it said would boost earnings and strengthen its presence in treatments for rare diseases.

  • 01/21/2018 23:58:28

    Healthcare group Sanofi agrees to buy U.S. peer Bioverativ for $11.6 billion

    PARIS (Reuters) - French healthcare group Sanofi has agreed to buy U.S. peer Bioverativ for $11.6 billion, in a deal which Sanofi said would boost its earnings and strengthen its presence in the field of treatments for rare diseases.

  • 01/21/2018 23:28:00

    Sanofi confirms deal to buy Bioverativ for $11.6 billion

    French healthcare group Sanofi has agreed to buy U.S. peer Bioverativ for $11.6 billion.

  • 01/21/2018 19:22:12

    Sanofi set to buy Bioverativ for more than $11.5 billion: WSJ

    (Reuters) - Sanofi SA is close to a deal to take over U.S. drug maker Bioverativ Inc for more than $11.5 billion, the Wall Street Journal reported, citing people familiar with the matter.

  • 01/08/2018 00:23:34

    BRIEF-Sanofi And Alnylam Pharmaceuticals Enter Into Partnership

    * AND ALNYLAM, ANNOUNCED ON SUNDAY STRATEGIC RESTRUCTURING OF RNAI THERAPEUTICS RARE DISEASE ALLIANCE

  • 01/07/2018 23:58:24

    Sanofi to market new hemophilia drug in deal with Alnylam

    PARIS, Jan 8 (Reuters) - French pharmaceutical group Sanofi said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with U.S. Alnylam Pharmaceuticals.

  • 12/12/2017 23:04:51

    BRIEF-Regeneron And Sanofi Announce Positive Topline Pivotal Results For Pd-1 Antibody Cemiplimab In Advanced Cutaneous ...

    Regeneron Pharmaceuticals Inc(REGN): * REGENERON AND SANOFI ANNOUNCE POSITIVE TOPLINE PIVOTAL RESULTS FOR PD-1 ANTIBODY CEMIPLIMAB IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA. * REGENERON PHARMACEUTICALS INC SAYS SAFETY PROFILE IN STUDY WAS GENERALLY CONSISTENT WITH APPROVED ANTI-PD-1 AGENTS.

  • 12/11/2017 12:04:25

    FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's (LLY) fast-acting insulin, Humalog. Admelog, generally taken just before meals, was approved for use in children older than three and adults with type 1 diabetes, as well as adults with type 2 diabetes.

  • 12/11/2017 12:04:06

    UPDATE 1-FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

    Dec 11 (Reuters) - The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog.

  • 12/11/2017 11:13:52

    FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog

    Dec 11 (Reuters) - The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog.

  • 12/04/2017 18:10:17

    Trial results of Zika vaccine Sanofi dropped show promise

    A Zika vaccine Sanofi SA dropped in September under political pressure over pricing produced strong responses in more than 90 percent of those taking part in an early-stage clinical trial, U.S. researchers reported on Monday. The results, published in the journal Lancet, offer a first glimpse at the vaccine's performance in people, and suggest it might have had a promising future.

  • 12/04/2017 12:58:08

    Trouble mounts for Sanofi dengue vaccine over safety concerns

    The World Health Organization said on Monday it hopes to review safety data on Sanofi's dengue vaccine this month, while the Philippines ordered an investigation of its now suspended massive immunization program after the French drugmaker said it could actually worsen the disease in some cases.

  • 12/04/2017 07:52:19

    Brazil recommends restrictions on Sanofi dengue vaccine

    The Brazilian government said on Monday it has suggested restrictions on the use of a dengue vaccine that has been suspended elsewhere after French drug company Sanofi SA said it could worsen the disease in some cases.

  • 12/03/2017 23:25:45

    Philippines orders probe into vaccine, Sanofi says no deaths reported

    MANILA (Reuters) - The Philippines ordered a probe on Monday into the immunization of more than 730,000 children with a dengue vaccine that has since been suspended, while French drug company Sanofi said no deaths had been reported as a result of the program.

  • 12/01/2017 15:37:25

    UPDATE 1-Sanofi ends development of C. difficile vaccine

    Dec 1 (Reuters) - Pharmaceutical company Sanofi SA said on Friday that it had ended development of an experimental vaccine for Clostridium difficile infection, after an early look at late-stage trial results indicated a low probability for success.

  • 12/01/2017 14:43:26

    Sanofi ends development of C. difficile vaccine

    Dec 1 (Reuters) - Pharmaceutical company Sanofi SA said on Friday that it had ended development of an experimental vaccine for Clostridium difficile infection, after an early look at late-stage trial results indicated a low probability for success.

  • 12/01/2017 09:23:19

    BioTelemetry's (BEAT) Telcare Unit Collaborates With Onduo

    BioTelemetry Inc s BEAT Telcare division recently signed a partnership agreement with Onduo a joint venture by Verily an Alphabet company and 160 Sanofi Per the agreement Telcare will act as an authorized provider of remote blood glucose systems along with the resulting data

  • 11/08/2017 05:50:01

    Regeneron's stock rallies after profit and sales rise above expectations

    Shares of Regeneron Pharmaceuticals Inc. rallied 2.6% in premarket trade Wednesday, after the biotechnology company reported third-quarter profit and revenue that rose above expectations. Net income increased to $388.3 million, or $3.32 a share, from $264.8 million, or $2.27 a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came to $3.99, beating the FactSet consensus of $3.82. Revenue rose to $1.50 billion from $1.22 billion, above the FactSet consensus of $1.45 billion, as net product sales, Sanofi collaboration revenue and Bayer collaboration revenue all beat expectations. Sales of its lead retinal therapy Eylea rose 12% to $953 million, beating the FactSet consensus of $935 million. The stock has fallen 14% over the past three months through Tuesday, while the iShares Nasdaq Biotechnology ETF has slipped 0.1% and the S&P 500 has gained 4.7%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/02/2017 01:32:27

    UPDATE 1-Sanofi refines expectations on drop in sales at diabetes arm

    PARIS, Nov 2 (Reuters) - Sanofi confirmed its 2017 outlook after it posted slightly lower-than-expected third-quarter results, and gave a more precise range on expectations of a sales decline at its embattled diabetes business.

  • 10/26/2017 01:39:40

    Pfizer sets date for auction of consumer healthcare unit: Reuters

    Pfizer Inc. will begin the auction process for its consumer healthcare unit in November, which it hopes will end in a $15 billion sale, Reuters reported late Wednesday, citing sources close to the matter. GlaxoSmithKline PLC. and Reckitt Benckiser are among those companies that have said they would consider bidding for the Pfizer unit. One of the sources told Reuters that initial discussions with Reckitt have already happened. Other possible bidders may include Procter & Gamble , Sanofi SA , Johnson & Johnson and Nestle [s: ch:nesn], sources said. The companies have been contacted for comment.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Santander Consumer USA Holdings Inc.SC | Santander Holdings USASOV^C | SAP SESAP | Saratoga Investment CorpSAQ | Saratoga Investment CorpSAR | Sasol Ltd.SSL | Saul CentersBFS | Saul CentersBFS^C | Scana CorporationSCG | Schlumberger N.V.SLB |